Shionogi & (4507) FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although the integration of Torii Pharmaceutical and the former JT Pharmaceutical Business, together with the launch of the RADICAVA U.S. business, resulted in substantial increases in revenue and profit, it should be noted that the growth in net income was boosted by a temporary tax factor involving the recognition of a negative corporate income tax expense. Revenue was ¥163.31B (+63.7% year on year), while operating income was ¥66.91B (+90.6%, with an operating margin of 41.0%). Profit before tax was ¥73.74B (+59.2%), whereas consolidated profit for the quarter was ¥97.72B (+148.3%), and profit attributable to owners of the parent was ¥97.696B (+148.2%), both showing growth exceeding that of profit before tax. The primary drivers of revenue growth were the sharp expansions in domestic prescription pharmaceuticals (+137.3%) and overseas subsidiaries/exports (+196.6%), while the main drivers of profit growth were operating leverage, other income of ¥27.77B, and the recognition of a corporate income tax benefit.

Factors Affecting Results

【Revenue】Revenue was ¥163.31B, representing a substantial 63.7% year-on-year increase. By product category, domestic prescription pharmaceuticals contributed ¥33.5B (+137.3%, reflecting the integration effects of Torii Pharmaceutical, Radicava, and other products), overseas subsidiaries/exports contributed ¥42.2B (+196.6%, driven by the launch of the RADICAVA U.S. business and growth of cefiderocol in Europe and the United States), and royalty income contributed ¥80.1B (+25.3%, driven by the expansion of ViiV’s HIV franchise). Contract manufacturing, however, declined to ¥4.0B (△11.0%).

【Profit and Loss】Operating income was ¥66.91B (+90.6%), and the operating margin was 41.0%, improving by +5.8pt from 35.2% in the prior-year period, reflecting operating leverage from higher revenue. The gross margin was 81.1%, down from 87.7% in the prior year (87,464/99,781), with increased amortization of intangible assets acting as a drag. While profit before tax was limited to ¥73.74B (+59.2%), profit for the quarter increased to ¥97.72B (+148.3%), 32.6% above profit before tax. The primary reason for this divergence was a negative corporate income tax expense of ¥23.98B, representing a tax benefit, resulting in an unusually low effective tax rate of -32.5%. This appears to be strongly influenced by temporary factors and will require normalization over the full year. In conclusion, the Company achieved increases in both revenue and profit.

Segment Analysis

Although the Company omits segment information because it operates as a single business—prescription pharmaceuticals—royalty income was the largest category based on the sales composition by product group, at ¥80.1B and 49.2% of total revenue, and can be regarded as the core business. Royalty income increased 25.3% due to the expansion of ViiV’s HIV franchise and supported results as a stable source of revenue. The primary drivers of revenue growth were domestic prescription pharmaceuticals (+137.3%) and overseas subsidiaries/exports (+196.6%), both reflecting the integration of Torii Pharmaceutical and the former JT Pharmaceutical Business as well as the launch of the RADICAVA U.S. business. Although the breakdown of operating profit by product category is not disclosed, a difference in profit margins may exist between the domestic and overseas businesses, where amortization of intangible assets is concentrated, and royalty income, which carries a smaller amortization burden.

Key Financial Metrics

Profitability: ROE 5.5% (quarterly result), operating margin 41.0% (up +5.8pt from 35.2% in the prior year)
R&D investment ratio: 19.5% (R&D expenses of ¥31.79B/revenue, down -5.5pt year on year)
Cash flow quality: Operating CF/net income of 0.44x (¥43.11B/¥97.72B; cash backing for earnings is weak at below 1.0x), FCF of -¥380.62B
Investment efficiency: Capital expenditures/depreciation and amortization of 0.22x (¥4.60B/¥20.88B; tangible investment is restrained at below 1.0x, indicating an investment phase focused on M&A)
Financial soundness: Equity ratio of 66.7% (65.3% in the prior year), current ratio of 113.8% (current assets of ¥926.65B/current liabilities of ¥814.43B)

Cash Flow Analysis

Operating CF increased 5.0% year on year to ¥43.11B, but its ratio to profit for the quarter of ¥97.72B remained at 0.44x, indicating weak cash backing for earnings. Investing CF showed a substantial outflow of -¥423.73B, primarily due to ¥391.88B in expenditures for business acquisitions, while capital expenditures were limited to ¥4.60B. Financing CF was -¥34.14B, mainly reflecting dividend payments of ¥32.46B. Free CF (operating CF + investing CF) was substantially negative at -¥380.62B, and cash and cash equivalents decreased by -¥412.46B from the beginning of the period to ¥298.94B. This represents a temporary cash outflow associated with a large-scale M&A transaction, and cash generation should be monitored.

Earnings Quality

Profit for the quarter of ¥97.72B exceeded profit before tax of ¥73.74B by 32.6%, indicating a boost above recurring earnings capacity. The primary factor was the recognition of a negative corporate income tax expense of ¥23.98B, representing a tax benefit, resulting in an effective tax rate of -32.5%. Other income of ¥27.77B accounted for 17.0% of revenue, exceeding the 5% threshold, and, based on the information disclosed in the PDF, appears to be related to ViiV-related equity-method investment gains and items not reflected in purchase price allocation (PPA). Given that operating CF was only 0.44x net income, non-cash and non-recurring factors made a substantial contribution to earnings for the period, and normalization is expected toward the full year.

Earnings Forecast and Guidance

Progress toward the full-year forecasts of revenue of ¥700.0B, operating income of ¥220.0B, and net income of ¥210.0B was 23.3%, 30.4%, and 46.5%, respectively. Compared with standard progress (Q1 = 25%), revenue was broadly in line with the standard level (-1.7pt), operating income was slightly ahead (+5.4pt), and net income was substantially ahead (+21.5pt). The substantial acceleration in net income progress is believed to be primarily attributable to the temporary factor of recognizing a negative corporate income tax expense, and normalization toward the second half of the fiscal year is anticipated. Neither the earnings forecast nor the dividend forecast was revised in the current quarter.

Shareholder Returns

The full-year dividend forecast is ¥76 per share, implying a payout ratio of 30.8% based on forecast EPS of ¥246.79. Dividend payments during Q1 were ¥32.46B, representing the finalized dividend for the previous fiscal period, and no share repurchases were conducted. Since no share repurchases were made, the term “payout ratio” is appropriate. Dividend payments were covered within operating CF of ¥43.11B; however, FCF was negative due to the substantial investing CF outflow, and the sustainability of shareholder returns in the near term will depend on trends in operating cash flow generation.

Catalysts

【Short Term】Regulatory filings in Europe and Asia based on the results of Phase 3 trials for olorofim; FDA review of the pediatric indication for cefiderocol (PDUFA date: February 23, 2027); and the analyst briefing scheduled for August 3, 2026.

【Long Term】Announcement of the integrated pipeline, comprising a total of 65 products including Torii Pharmaceutical and the former JT Pharmaceutical Business, at the R&D briefing scheduled for November 18, 2026; development to extend the dosing intervals of ViiV’s long-acting injectable (LAI) formulations, transitioning to three-times-yearly and twice-yearly dosing; and expansion of the RADICAVA U.S. business and the XOCOVA U.S. rollout.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Return

Both the operating margin and net profit margin substantially exceeded the industry median, placing the Company at the top end of the industry. However, it should be noted that the divergence in the net profit margin includes temporary factors such as the tax benefit.

Growth and Capital Efficiency

The revenue growth rate substantially exceeded the industry median and demonstrated exceptional growth within the industry.

※Source: Compiled by the Company

Risk Factors

1. Risk of reversal of temporary tax factors: Corporate income tax expense was negative at ¥23.98B for the period, representing a tax benefit, and the effective tax rate was -32.5%. Profit for the quarter of ¥97.72B exceeded profit before tax of ¥73.74B by 32.6%, and the EPS growth rate may slow as the tax rate normalizes over the full year.

2. Changes in asset composition and amortization/impairment risk associated with M&A: Intangible assets increased sharply by +198.9% from the end of the previous fiscal year (¥188.04B→¥562.12B), while goodwill increased +119.5% (¥29.22B→¥64.12B). Intangible assets reached 21.2% of total assets, and amortization of product-related intangible assets of ¥15.82B was recognized during the current period alone. Trends in future amortization expenses and impairment losses must therefore be monitored.

3. Cash flow and liquidity: Operating CF was ¥43.11B, only 0.44x profit for the quarter, indicating relatively weak cash backing for earnings. Primarily due to ¥391.88B in expenditures for business acquisitions, investing CF was substantially negative at -¥423.73B, and FCF was -¥380.62B. Bonds and borrowings of ¥660.0B are included in current liabilities, requiring close attention to liquidity and maturity management.

Key Earnings Highlights

1. The increases in revenue and profit were driven by the integration effects of Torii Pharmaceutical and the former JT Pharmaceutical Business as well as the launch of the RADICAVA U.S. business, with the operating margin improving +5.8pt year on year to 41.0%. Royalty income from ViiV’s HIV franchise, which accounted for 49.2% of the revenue mix, served as the core business supporting results.

2. Net income was reported at a level 32.6% above profit before tax, with the temporary tax factor of recognizing a negative corporate income tax expense contributing to the result. Depending on full-year tax rate trends, the net income growth rate may fluctuate toward the second half of the fiscal year.

3. Progress toward the full-year targets was ahead of the standard pace of 25%, with operating income at 30.4% and net income at 46.5%. However, given the substantial contribution from non-recurring income and tax factors, the extent of normalization in the first-half and full-year results will be a key focus going forward.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade period). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥2,289–¥2,427 for cost of equity ±1%; ¥2,349–¥2,367 for ω ±0.1.

Notes:

• Since net income progress toward the full-year forecast (47%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual income model / Interest rate reference month: 2026-06 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI through the integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

Shionogi delivered an exceptionally strong FY2027 Q1 earnings result, although the headline net-profit acceleration was materially supported by non-recurring and tax-related items. Revenue rose 63.7% year on year to JPY163.3bn. Operating income increased 90.6% to JPY66.9bn. Operating margin expanded by 580 basis points to 41.0% from 35.2% in the prior-year quarter. Gross margin, however, declined by 660 basis points to 81.1% from 87.7%, indicating that higher product costs and acquired-product amortization diluted the underlying revenue margin. SG&A rose 74.9% to JPY45.2bn, faster than revenue growth, and increased to 27.6% of sales from 25.9%. R&D expense increased 27.7% to JPY31.8bn, but R&D intensity declined to 19.5% of revenue from 24.9%, remaining within the normal range for an innovator pharmaceutical company. Operating profit benefited from JPY27.8bn of other income, compared with only JPY0.9bn a year earlier. Net income increased 148.2% to JPY97.7bn, substantially exceeding pre-tax profit of JPY73.7bn because the company recorded a JPY24.0bn income-tax benefit. Consequently, the 59.8% net margin and 22.0% annualized ROE are not representative of a normal recurring tax profile. Cash generation was positive but lagged accounting earnings, with operating cash flow of JPY43.1bn equating to only 0.44x net income. The principal reason for the weak cash-conversion ratio is the combination of a large tax benefit in net income, non-cash equity-method income and adverse working-capital movements. The company completed JPY391.9bn of business acquisitions during the quarter, driving investing cash outflow to JPY423.7bn and free cash flow to negative JPY380.6bn. This acquisition substantially increased intangible assets and goodwill, making successful commercial integration and the realization of pipeline/product-rights value central to the forward earnings case. Despite the acquisition-related cash deployment, the balance sheet remains well capitalized, with a 66.7% equity ratio and debt-to-equity ratio of 0.50x. Management retained its full-year forecast, and Q1 operating-profit progress of 30.4% is ahead of the normal 25% seasonal benchmark. Full-year sales progress is 23.3%, slightly below the benchmark, while net-income progress is 46.5% and is likely elevated by Q1 tax benefits and other income. The principal forward implication is that reported FY2027 earnings will need to be assessed against the sustainability of acquired-asset revenue, amortization burden, equity-method contribution and normalization of tax effects rather than Q1 headline net income alone.

Profitability Analysis

The reported annualized 22.0% ROE is decomposed into a 59.8% net profit margin, 0.246x asset turnover and 1.50x financial leverage. The dominant driver of the strong annualized ROE is the unusually high net margin rather than aggressive balance-sheet leverage: leverage is moderate and the equity ratio is high at 66.7%. The net margin was boosted by a JPY24.0bn income-tax benefit, resulting in a tax burden of 1.325x, and therefore should not be regarded as a normalized profitability level. The 1.102x interest burden is above 1.0x because net finance income exceeded finance costs, indicating that financing did not constrain earnings. Operating profitability was nevertheless strong, with a 41.0% operating margin, well above the 15% benchmark for excellent profitability. Revenue growth of 63.7% outpaced R&D growth of 27.7%, creating scale benefits and lowering R&D intensity by 540 basis points. Conversely, SG&A grew 74.9%, 11.2 percentage points faster than revenue, and its sales ratio rose by 170 basis points; this is a cost discipline item to monitor as the company commercializes acquired products and assets. Gross margin compression of 660 basis points was significant, reflecting cost of sales growth of 149.9% and product-related intangible amortization of JPY15.8bn. The operating-margin expansion despite lower gross margin was mainly supported by JPY27.8bn of other income and operating scale. Thus, the Q1 margin outcome combines robust commercial momentum with items that may not recur at the same level. The reported annualized asset turnover of 0.246x is low in absolute terms, consistent with a pharmaceutical balance sheet carrying substantial equity-method investments and intangible assets. The sharp increase in intangible assets after acquisition further raises the importance of revenue realization and post-acquisition return on invested capital.

Growth Assessment

Q1 revenue growth of 63.7% to JPY163.3bn demonstrates a substantial step-up in the earnings base. Operating income grew faster than sales at 90.6%, evidencing positive operating leverage at the reported operating-profit level. However, the growth mix includes JPY27.8bn of other income, and this contribution needs to be separated from recurring product and royalty economics when assessing sustainable operating momentum. Product-related intangible amortization increased to JPY15.8bn from JPY0.5bn in the prior-year quarter, consistent with the enlarged acquired intangible-asset base and creating a continuing charge against operating profit. R&D spending of JPY31.8bn, equal to 19.5% of revenue, supports continued investment in discovery and development while remaining aligned with the 15-20% innovator-pharma benchmark. The company operates as a single pharmaceutical business, with research, development, manufacturing and sales managed on an integrated basis. Q1 sales reached 23.3% of the JPY700.0bn full-year forecast, 1.7 percentage points below the standard first-quarter progress rate of 25%. Operating income reached 30.4% of the JPY220.0bn full-year forecast, 5.4 percentage points ahead of the seasonal benchmark. Net income reached 46.5% of the JPY210.0bn full-year forecast, 21.5 percentage points above the benchmark, but this degree of outperformance is not a reliable run-rate given the tax benefit. The full-year forecast assumes sales growth, operating-income growth and reported net-income growth patterns that will require continued commercial delivery after the Q1 acquisition. The growth outlook is therefore constructive at the operating level but increasingly dependent on acquisition integration, acquired IP monetization, pricing conditions and the persistence of non-core income items.

Financial Health

Financial health remains sound despite the very large acquisition outlay. Total equity increased to JPY1,772.8bn from JPY1,690.3bn at the preceding fiscal year-end, supported by Q1 comprehensive income of JPY115.4bn net of JPY33.0bn of dividends. The equity ratio improved to 66.7% from 65.3%, providing a substantial loss-absorption buffer. Debt-to-equity is 0.50x, well below the 2.0x threshold that would indicate aggressive leverage. Current assets of JPY926.7bn exceed current liabilities of JPY814.4bn, implying a current ratio of approximately 1.14x; this is above 1.0x, so there is no immediate current-liquidity warning, but it is below the 1.5x healthy benchmark. The JPY660.0bn of bonds and borrowings are classified as current, representing a material refinancing and maturity-management consideration. Liquidity is supported by JPY298.9bn of cash and equivalents and JPY315.8bn of other current financial assets, which together exceed current borrowings. Lease liabilities total JPY241.3bn, comprising JPY58.4bn current and JPY182.9bn non-current, and should be considered alongside borrowing obligations. Intangible assets increased by JPY374.1bn, or 198.9% year on year, to JPY562.1bn, equivalent to 21.2% of total assets. Goodwill increased by JPY34.9bn, or 119.5%, to JPY64.1bn. Although goodwill represents only 3.6% of equity and does not currently create a balance-sheet concentration concern, the enlarged intangible asset base makes future earnings more sensitive to product-rights amortization and impairment testing. Investments accounted for using the equity method are JPY720.5bn, or 27.1% of total assets, making affiliate performance and distributions financially important. The acquisition did not increase reported short-term borrowings during Q1, but it reduced cash sharply, so maintaining liquid financial assets and managing debt maturities are key.

Notable B/S Changes

Intangible assets: +JPY374.1bn (+198.9% YoY) to JPY562.1bn, or 21.2% of total assets - reflects the acquisition-led expansion of product and IP assets; monitor amortization, commercialization performance and impairment risk. Goodwill: +JPY34.9bn (+119.5% YoY) to JPY64.1bn - confirms an acquisition-related increase in M&A exposure, although goodwill remains modest at 3.6% of equity. Cash and equivalents: -JPY412.5bn from the preceding fiscal year-end to JPY298.9bn - primarily reflects acquisition spending and increases the importance of liquidity and maturity management. Deferred tax assets: +JPY327.6bn from the preceding fiscal year-end to JPY37.1bn - consistent with the unusually large Q1 tax benefit and a key item for assessing the repeatability of reported net profit.

Cash Flow Quality

Cash-flow quality requires attention because operating cash flow of JPY43.1bn was only 44% of net income of JPY97.7bn, below the 0.8x quality threshold. The low OCF-to-net-income ratio is partly explained by the JPY24.0bn tax benefit that increased accounting profit without a corresponding operating cash inflow. It is also affected by JPY26.8bn of equity-method profit, which is non-cash at recognition, although JPY28.9bn of dividends from equity-method investees was received during the quarter. Working capital was a further drag: receivables increased by JPY2.3bn, inventories increased by JPY3.1bn and payables decreased by JPY22.9bn. The decline in payables was the largest working-capital cash outflow and reduced conversion of operating earnings into cash. Quality alerts also indicate receivable days of 97, inventory days of 323 and a cash conversion cycle of 357 days. These elevated days metrics indicate a large amount of cash tied up in customer balances and inventories relative to the annualized revenue and cost base, which is particularly relevant in a pharmaceutical supply chain where inventory may reflect launch, manufacturing and distribution planning. The inventory-days alert is material because 323 days is well above both the 90-day pharmaceutical-monitoring threshold and the stricter 60-day alert threshold. The long cash conversion cycle may be partly structural for pharmaceuticals and acquired-product supply chains, but the direction of payables and inventory movements warrants monitoring for post-acquisition integration effects. Capital expenditure was modest at JPY4.6bn, and operating cash flow less capital expenditure was positive at approximately JPY38.5bn. Reported free cash flow was negative JPY380.6bn because it includes the JPY391.9bn business acquisition. This negative free cash flow therefore principally reflects discretionary strategic investment rather than an inability of the core business to generate operating cash. Nevertheless, recurring operating cash flow did not cover the acquisition and JPY32.5bn parent-owner dividend payment combined, resulting in a JPY412.5bn quarterly decline in cash and equivalents. The acquisition’s future cash return and the normalization of working-capital conversion are the critical tests of cash-flow quality.

Dividend Sustainability

The company paid JPY32.5bn of dividends attributable to owners during Q1, with no share repurchases. Against Q1 profit attributable to owners of JPY97.7bn, the cash dividend represented approximately 33% of quarterly earnings. The full-year dividend forecast is JPY76.0 per share, compared with forecast EPS of JPY246.79, implying a forecast dividend payout ratio of approximately 30.8%. This is comfortably below the 60% sustainability benchmark. Since there were no buybacks, the dividend payout ratio and total return ratio are effectively the same measure for the period. Operating cash flow of JPY43.1bn covered the JPY32.5bn dividend and JPY4.6bn capital expenditure during Q1, leaving a modest positive pre-acquisition cash surplus. However, reported free cash flow was negative after the large business acquisition, so acquisition funding rather than ordinary dividends is the immediate driver of balance-sheet cash usage. The high equity ratio and liquid financial-asset holdings provide support for the current shareholder-return policy. Dividend sustainability is therefore sound on the stated full-year earnings and ordinary operating-cash-flow profile, but the pace of further acquisitions, integration spending, acquired-asset performance and debt refinancing should be monitored.

Risk Assessment

Business risks include Pharmaceutical commercialization and integration risk is elevated after JPY391.9bn of business acquisitions in Q1, equal to 240.0% of quarterly revenue. Failure to realize expected sales, synergies or pipeline value could weaken returns on the acquired assets., Intangible-asset execution risk is material: intangible assets are JPY562.1bn, or 21.2% of total assets, and product-related intangible amortization was JPY15.8bn in Q1. Product underperformance, regulatory setbacks, pricing pressure or loss of exclusivity could lead to impairment risk or lower profitability., Pharmaceutical industry risks include clinical-development failure, regulatory approval uncertainty, reimbursement reform, price controls and generic competition. These risks can affect both acquired products and internally developed assets., The 323-day inventory period and 357-day cash conversion cycle create operational risk around demand forecasting, manufacturing planning, distribution inventories and potential obsolescence., A JPY720.5bn equity-method investment balance exposes earnings and cash receipts to the performance, dividend capacity and strategic decisions of affiliates..

Financial risks include The OCF-to-net-income ratio of 0.44x is below the 0.8x alert threshold. The root cause is the tax benefit, non-cash equity-method profit and adverse working-capital movements; the impact is that headline earnings currently overstate near-term cash conversion., Current borrowings of JPY660.0bn are material relative to the JPY814.4bn current-liability base. Although liquid assets provide coverage, refinancing and liquidity management remain important after the cash balance declined by JPY412.5bn in Q1., Acquisition spending drove negative reported free cash flow of JPY380.6bn. The impact is reduced financial flexibility if similarly large acquisitions recur before acquired operations generate cash returns., Receivable days of 97 exceed the 60-day alert threshold. This may reflect customer terms and revenue mix, but it increases collection and counterparty risk and contributes to the long cash conversion cycle..

Key concerns include The Q1 59.8% net margin and 22.0% annualized ROE are flattered by a JPY24.0bn tax benefit and should not be extrapolated as normalized profitability., Other income of JPY27.8bn was a significant contributor to operating income; recurrence and composition are important for evaluating underlying earnings momentum., SG&A growth of 74.9% exceeded revenue growth of 63.7%, while gross margin fell 660 basis points. Sustained operating-margin expansion therefore depends on controlling commercialization and integration costs., Active-acquirer status is a material risk flag: the 240.0% acquisition-to-revenue ratio is far above the 10% aggressive-acquirer threshold. The impact on the investment case is a greater dependence on management's capital-allocation discipline and post-deal execution., Inventory days of 323 are unusually high. This is a second, independent inventory alert under both the 90-day and 60-day thresholds and increases the importance of monitoring inventory write-downs and inventory-to-sales normalization..

Investment Implications

Key takeaways include Reported Q1 growth was strong, with revenue up 63.7% and operating income up 90.6%, but net income was amplified by a tax benefit., Operating margin expanded to 41.0%, although gross-margin compression and faster SG&A growth temper the apparent operating leverage., The business acquisition transformed the asset mix, with intangible assets rising 198.9% year on year and acquisition cash outflow reaching JPY391.9bn., The balance sheet remains conservatively capitalized, but current borrowing maturity management and post-acquisition liquidity are increasingly relevant., Ordinary operating cash flow covered dividends and capital expenditure, while acquisition spending was the principal cause of negative reported free cash flow..

Metrics to watch include Revenue and operating-profit conversion against the JPY700.0bn and JPY220.0bn full-year forecasts, Recurring operating margin excluding other income and the pace of product-related intangible amortization, OCF-to-net-income ratio, receivable days, inventory days and the cash conversion cycle, Revenue, profitability and cash contribution from the acquired business and assets, Intangible-asset impairment indicators, including commercial performance, regulatory developments and patent/exclusivity developments, Cash and current financial assets relative to JPY660.0bn of current bonds and borrowings, Dividend payout ratio relative to normalized earnings and operating cash flow.

Regarding relative positioning, Shionogi displays profitability and capitalization characteristics stronger than standard broad-market thresholds, including a 41.0% operating margin, 66.7% equity ratio and 0.50x debt-to-equity ratio. Relative to innovator-pharma norms, its 19.5% R&D intensity is appropriately positioned. Its relative weaknesses are cash conversion, unusually long working-capital days and heightened acquisition-execution exposure rather than excessive reported financial leverage.